What is new in chronic lymphocytic leukemia (CLL)? (Episode1)
0 Views
administrator
07/08/23
The ALPINE phase 3 study showed a head-to-head comparison between two Bruton’s tyrosine kinase (BTK) inhibitors: ibrutinib and zanubrutinib, which has a greater specificity, as treatment for relapsed or refractory CLL or small lymphocytic lymphoma (SLL).
Results of progression free survival (PFS) and safety of both BTKs were recently published in 2023.
Dr. Ahmed Magdy is highlighting the interesting results of PFS and safety profile of both agents.
-
Category
Show more
Facebook Comments
No comments found